EMA Medicine safety communications
Spikevax (previously COVID-19 Vaccine Moderna): adverse event
Published by European Medicines Agency:
Summary
Adverse event
Medicine
Spikevax (previously COVID-19 Vaccine Moderna)
- Category
- Medicine safety communications
- Product type
- Human medicine
- Active substance(s): CX-024414 (single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2)
- Therapeutic area: COVID-19 virus infection
- ATC code: J07BX03
Measures and alternatives
- Regulatory outcome: Variation
Source: EMA — medicine safety communications — European Medicines Agency
Source: European Medicines Agency (EMA). Reproduced with acknowledgement of the source, in line with the EMA legal notice. EU Safety Radar is an independent information service; the text above presents the official data in the original language — the notice published by the authority is authoritative.
Open the original notice (www.ema.europa.eu) ↗